RT Journal Article
SR Electronic
T1 CRISPR-based assays for point of need detection and subtyping of influenza
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.26.23290593
DO 10.1101/2023.05.26.23290593
A1 Zhang, Yibin B.
A1 Arizti-Sanz, Jon
A1 Bradley, A’Doriann
A1 Kosoko-Thoroddsen, Tinna-Solveig F.
A1 Sabeti, Pardis C.
A1 Myhrvold, Cameron
YR 2023
UL http://medrxiv.org/content/early/2023/06/03/2023.05.26.23290593.abstract
AB The high disease burden of influenza virus poses a significant threat to human health and requires better methods to rapidly detect its many circulating species, subtypes, and variants. No current diagnostic technology meets the combined critical needs for a rapid, sensitive, specific, and cost-effective method for point-of-need (PON) influenza detection and discrimination with minimal equipment requirements. Here, we introduce such a method using SHINE (Streamlined Highlighting of Infections to Navigate Epidemics), a CRISPR-based RNA detection platform. We develop and validate four SHINE assays for the detection and differentiation of clinically relevant influenza species (A and B) and subtypes (H1N1 and H3N2). These optimized assays achieve 100% concordance with reverse-transcriptase real-time polymerase chain reaction (RT-qPCR) when tested on clinical samples. We also created duplex Cas12/Cas13 SHINE assays to simultaneously detect two targets and demonstrate its use in discriminating two alleles of an oseltamivir resistance (H275Y) mutation as well as to detect influenza A and human RNAse P, as a built-in internal control. Our assays have the potential to expand influenza detection outside of clinical laboratories in order to enhance influenza diagnosis and surveillance.Competing Interest StatementJ.A.-S., P.C.S., and C.M. are inventors on a pending patent application held by the Broad Institute (International Patent Application No. PCT/US2021/049145), which covers the SHINE technology. P.C.S. is a co-founder of, shareholder in, and consultant to Sherlock Biosciences, Inc. and Delve Bio, as well as a Board member of and shareholder in Danaher Corporation. C.M. is a co-founder of Carver Biosciences, a startup company developing Cas13-based antivirals, and holds equity in Carver Biosciences. All other authors declare no competing interests.Funding StatementFunding was provided by the Defense Advanced Research Projects Agency (no. D18AC00006) and the Centers for Disease Control (no. 75D30122C15113). This work was also made possible by support from the Flu Laboratory and a cohort of generous donors through TEDs Audacious Project, including the ELMA Foundation, MacKenzie Scott, Skoll Foundation and Open Philanthropy. P.C.S. was also supported by the Merck KGaA Future Insight Prize.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:De-identified nasopharyngeal (NP) swabs (in UTM or VTM) from patients with influenza-like symptoms over the 2020-2021 influenza season (October - February) were provided to the Broad Institute by the CDC (USA). An additional non-human subjects research determination (NHSR-4318) and exempt determination (EX-7209) were made by the Broad Institute. This study was also reviewed by the CDC and was considered to not be human subject research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.